A citation-based method for searching scientific literature

Daniele Frisone, Alex Friedlaender, Umberto Malapelle, Giuseppe Banna, Alfredo Addeo. Crit Rev Oncol Hematol 2020
Times Cited: 26







List of co-cited articles
230 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
David Planchard, Benjamin Besse, Harry J M Groen, Pierre-Jean Souquet, Elisabeth Quoix, Christina S Baik, Fabrice Barlesi, Tae Min Kim, Julien Mazieres, Silvia Novello,[...]. Lancet Oncol 2016
500
38

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
David Planchard, Egbert F Smit, Harry J M Groen, Julien Mazieres, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M D'Amelio, Pingkuan Zhang, Bijoyesh Mookerjee,[...]. Lancet Oncol 2017
476
38

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.
Alex Friedlaender, Alexander Drilon, Glen J Weiss, Giuseppe L Banna, Alfredo Addeo. Cancer Treat Rev 2020
56
34

Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC.
Alex Friedlaender, Giuseppe Banna, Sandip Patel, Alfredo Addeo. Curr Treat Options Oncol 2019
27
30

Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario.
Alfredo Addeo, Fabrizio Tabbò, Tim Robinson, Lucio Buffoni, Silvia Novello. Crit Rev Oncol Hematol 2018
32
23

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
23

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.
Alessandro Leonetti, Francesco Facchinetti, Giulio Rossi, Roberta Minari, Antonia Conti, Luc Friboulet, Marcello Tiseo, David Planchard. Cancer Treat Rev 2018
73
23

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
Florian Guisier, Catherine Dubos-Arvis, Florent Viñas, Helene Doubre, Charles Ricordel, Stanislas Ropert, Henri Janicot, Marie Bernardi, Pierre Fournel, Régine Lamy,[...]. J Thorac Oncol 2020
112
23

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
Elizabeth Dudnik, Nir Peled, Hovav Nechushtan, Mira Wollner, Amir Onn, Abed Agbarya, Mor Moskovitz, Shoshana Keren, Noa Popovits-Hadari, Damien Urban,[...]. J Thorac Oncol 2018
102
23

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer,[...]. Lancet Oncol 2018
468
23

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko,[...]. Lancet 2019
19

Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study.
Irena Tan, Thomas E Stinchcombe, Neal E Ready, Jeffrey Crawford, Michael B Datto, Rebecca J Nagy, Richard B Lanman, Lin Gu, Jeffrey M Clarke. Transl Lung Cancer Res 2019
13
38

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Axel Hauschild, Jean-Jacques Grob, Lev V Demidov, Thomas Jouary, Ralf Gutzmer, Michael Millward, Piotr Rutkowski, Christian U Blank, Wilson H Miller, Eckhart Kaempgen,[...]. Lancet 2012
19


Targeting BRAF mutations in non-small cell lung cancer.
Connor Gerard O'Leary, Vladamir Andelkovic, Rahul Ladwa, Nick Pavlakis, Caicun Zhou, Fred Hirsch, Derek Richard, Kenneth O'Byrne. Transl Lung Cancer Res 2019
30
19

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.
J Mazieres, C Cropet, L Montané, F Barlesi, P J Souquet, X Quantin, C Dubos-Arvis, J Otto, L Favier, V Avrillon,[...]. Ann Oncol 2020
62
19

Targeting Alterations in the RAF-MEK Pathway.
Rona Yaeger, Ryan B Corcoran. Cancer Discov 2019
170
19

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
Stephanie Cardarella, Atsuko Ogino, Mizuki Nishino, Mohit Butaney, Jeanne Shen, Christine Lydon, Beow Y Yeap, Lynette M Sholl, Bruce E Johnson, Pasi A Jänne. Clin Cancer Res 2013
241
19

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
Oliver Gautschi, Julie Milia, Bastien Cabarrou, Marie-Virginia Bluthgen, Benjamin Besse, Egbert F Smit, Juergen Wolf, Solange Peters, Martin Früh, Dieter Koeberle,[...]. J Thorac Oncol 2015
115
19

Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study.
Vivek Subbiah, Radj Gervais, Gregory Riely, Antoine Hollebecque, Jean-Yves Blay, Enriqueta Felip, Martin Schuler, Anthony Gonçalves, Antonio Italiano, Vicki Keedy,[...]. JCO Precis Oncol 2019
29
19

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
David Planchard, Tae Min Kim, Julien Mazieres, Elisabeth Quoix, Gregory Riely, Fabrice Barlesi, Pierre-Jean Souquet, Egbert F Smit, Harry J M Groen, Ronan J Kelly,[...]. Lancet Oncol 2016
266
19

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
750
19

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
474
19


Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.
Amir Noeparast, Erik Teugels, Philippe Giron, Gil Verschelden, Sylvia De Brakeleer, Lore Decoster, Jacques De Grève. Oncotarget 2016
70
15

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.
Andrea Casadei Gardini, Elisa Chiadini, Luca Faloppi, Giorgia Marisi, Angelo Delmonte, Mario Scartozzi, Cristian Loretelli, Alessandro Lucchesi, Devil Oboldi, Alessandra Dubini,[...]. BMC Cancer 2016
25
16

Clinical characteristics and course of 63 patients with BRAF mutant lung cancers.
Anya M Litvak, Paul K Paik, Kaitlin M Woo, Camelia S Sima, Matthew D Hellmann, Maria E Arcila, Marc Ladanyi, Charles M Rudin, Mark G Kris, Gregory J Riely. J Thorac Oncol 2014
84
15

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Matthew Dankner, April A N Rose, Shivshankari Rajkumar, Peter M Siegel, Ian R Watson. Oncogene 2018
180
15

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, Caroline Robert, John B Haanen, Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio,[...]. N Engl J Med 2011
15

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Paolo A Ascierto, Grant A McArthur, Brigitte Dréno, Victoria Atkinson, Gabrielle Liszkay, Anna Maria Di Giacomo, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas,[...]. Lancet Oncol 2016
571
15

Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.
Roxana Reyes, Clara Mayo-de-Las-Casas, Cristina Teixidó, Carlos Cabrera, Elba Marín, Ivan Vollmer, Pedro Jares, Mónica Garzón, Miguel Ángel Molina-Vila, Noemí Reguart. Clin Lung Cancer 2019
10
40

Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples.
Francesco Pepe, Caterina De Luca, Riccardo Smeraglio, Pasquale Pisapia, Roberta Sgariglia, Mariantonia Nacchio, Maria Russo, Nicola Serra, Danilo Rocco, Ciro Battiloro,[...]. J Clin Pathol 2019
27
15

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.
Antonio Marchetti, Lara Felicioni, Sara Malatesta, Maria Grazia Sciarrotta, Luigi Guetti, Antonio Chella, Patrizia Viola, Carmela Pullara, Felice Mucilli, Fiamma Buttitta. J Clin Oncol 2011
364
15

A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.
María Sereno, Victor Moreno, Juan Moreno Rubio, César Gómez-Raposo, Sagrario García Sánchez, Rebeca Hernández Jusdado, Sandra Falagan, Francisco Zambrana Tébar, Enrique Casado Sáenz. Anticancer Drugs 2015
20
20

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
Zhan Yao, Rona Yaeger, Vanessa S Rodrik-Outmezguine, Anthony Tao, Neilawattie M Torres, Matthew T Chang, Matthias Drosten, Huiyong Zhao, Fabiola Cecchi, Todd Hembrough,[...]. Nature 2017
278
15

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
15

Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
Umberto Malapelle, Clara Mayo de-Las-Casas, Danilo Rocco, Monica Garzon, Pasquale Pisapia, Nuria Jordana-Ariza, Maria Russo, Roberta Sgariglia, Caterina De Luca, Francesco Pepe,[...]. Br J Cancer 2017
90
15

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
598
15

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
11

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Fred R Hirsch, Abigail McElhinny, Dave Stanforth, James Ranger-Moore, Malinka Jansson, Karina Kulangara, William Richardson, Penny Towne, Debra Hanks, Bharathi Vennapusa,[...]. J Thorac Oncol 2017
855
11

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
A Lisberg, A Cummings, J W Goldman, K Bornazyan, N Reese, T Wang, P Coluzzi, B Ledezma, M Mendenhall, J Hunt,[...]. J Thorac Oncol 2018
299
11

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, Matthew D Hellmann, Mark M Awad, Justin F Gainor, Alexa B Schrock, Ryan J Hartmaier, Sally E Trabucco, Laurie Gay,[...]. Cancer Discov 2018
742
11

The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience.
Javier Torralvo, Alex Friedlaender, Verane Achard, Alfredo Addeo. Cancer Genomics Proteomics 2019
36
11

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, Bogdan Zurawski, Sang-We Kim, Enric Carcereny Costa, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez,[...]. N Engl J Med 2019
11

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
535
11

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Alice T Shaw, Benjamin J Solomon, Rita Chiari, Gregory J Riely, Benjamin Besse, Ross A Soo, Steven Kao, Chia-Chi Lin, Todd M Bauer, Jill S Clancy,[...]. Lancet Oncol 2019
149
11

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Alexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, Herbert H F Loong, Melissa Johnson, Justin Gainor, Caroline E McCoach, Oliver Gautschi, Benjamin Besse, Byoung C Cho,[...]. N Engl J Med 2020
253
11

The METeoric rise of MET in lung cancer.
Alex Friedlaender, Alexander Drilon, Giuseppe Luigi Banna, Solange Peters, Alfredo Addeo. Cancer 2020
15
20

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
Paul K Paik, Maria E Arcila, Michael Fara, Camelia S Sima, Vincent A Miller, Mark G Kris, Marc Ladanyi, Gregory J Riely. J Clin Oncol 2011
468
11

The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients.
Quan Lin, Haoran Zhang, Huaxin Ding, Jun Qian, Analyn Lizaso, Jing Lin, Han Han-Zhang, Jianxing Xiang, Yuping Li, Hong Zhu. J Transl Med 2019
23
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.